Literature DB >> 29562983

Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.

K M Little1, M Khundi2, G L Barnes3, L G Ngwira2, A Nkhoma2, S Makombe4, E L Corbett5, R E Chaisson3, D W Dowdy1.   

Abstract

SETTING: To reduce the risk of tuberculosis (TB) among individuals with human immunodeficiency virus (HIV) infection, the World Health Organization recommends at least 6 months of isoniazid preventive therapy (IPT). Completion of IPT remains a major challenge in resource-limited settings.
OBJECTIVE: To evaluate predictors of IPT completion in individuals newly diagnosed with HIV.
DESIGN: Predictors of IPT completion among adults newly diagnosed with HIV in rural Malawi were evaluated using a multilevel logistic regression model.
RESULTS: Of 974 participants who screened negative for active TB and were started on IPT, 732 (75%) completed treatment. Only one IPT-eligible individual refused treatment. Participants who were aged <25 years (compared with those aged 45 years, adjusted OR [aOR] 0.33, 95%CI 0.18-0.60) and male (compared to non-pregnant females, aOR 0.57, 95%CI 0.37-0.88) had lower odds of IPT completion.
CONCLUSION: IPT provision at the time of initial HIV diagnosis was highly acceptable in rural Malawi; three quarters of those who initiated IPT successfully completed therapy. We observed lower odds of completion among males and among female participants aged <25 years. Additional efforts may be needed to ensure IPT completion among males and young females who have recently been diagnosed with HIV.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29562983      PMCID: PMC6417104          DOI: 10.5588/ijtld.16.0836

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

Review 1.  Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Authors:  Nicole Salazar-Austin; David W Dowdy; Richard E Chaisson; Jonathan E Golub
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

2.  Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.

Authors:  Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez
Journal:  AIDS Care       Date:  2019-06-10

3.  Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.

Authors:  Govinda Prasad Dhungana; Pruthu Thekkur; Palanivel Chinnakali; Usha Bhatta; Basudev Pandey; Wei-Hong Zhang
Journal:  BMJ Open       Date:  2019-05-29       Impact factor: 2.692

4.  To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.

Authors:  Mahendra M Reddy; Pruthu Thekkur; Nagesh Ramya; Prasanna B T Kamath; Suresh G Shastri; Ravi B N Kumar; Palanivel Chinnakali; Abhay S Nirgude; Chethana Rangaraju; Narasimhaiah Somashekar; Ajay M V Kumar
Journal:  Glob Health Action       Date:  2020       Impact factor: 2.640

5.  Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.

Authors:  Muthoni Karanja; Leonard Kingwara; Philip Owiti; Elvis Kirui; Faith Ngari; Richard Kiplimo; Maurice Maina; Enos Masini; Elizabeth Onyango; Catherine Ngugi
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

6.  Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).

Authors:  Scott A Nabity; Laurence J Gunde; Diya Surie; Ray W Shiraishi; Hannah L Kirking; Alice Maida; Andrew F Auld; Michael Odo; Andreas Jahn; Rose K Nyirenda; John E Oeltmann
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

7.  Mixed methods systematic review and metasummary about barriers and facilitators for the implementation of cotrimoxazole and isoniazid-Preventive therapies for people living with HIV.

Authors:  Pia Müller; Luís Velez Lapão
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

8.  Isoniazid preventive therapy-related adverse events among Malawian adults on antiretroviral therapy: A cohort study.

Authors:  Lufina Tsirizani-Galileya; Elasma Milanzi; Randy Mungwira; Titus Divala; Jane Mallewa; Donnie Mategula; Nginache Nampota; Victor Mwapasa; Andrea Buchwald; Matthew B Laurens; Miriam K Laufer; Joep J Van Oosterhout
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

9.  Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil.

Authors:  Camila Melo Picone; Angela Carvalho Freitas; Eliana B Gutierrez; Vivian Iida Avelino-Silva
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-02-07       Impact factor: 1.846

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.